Recent actions by the Food and Drug Administration (FDA) to approve a new generic version of the abortion pill mifepristone under the Trump administration have drawn heavy criticism from some conservatives. The backlash stems from the view that the decision undermines the anti-abortion movement and increases access to abortion. Background on the generic drug approval On or around September 30, 2025, the FDA approved a generic version of mifepristone from the drugmaker Evita Solutions. Mifepristo